Epigenetic Drugs for Cancer and microRNAs: A Focus on Histone Deacetylase Inhibitors

Pierre Autin 1 Christophe Blanquart 1 Delphine Fradin 1, *
* Corresponding author
1 CRCINA - Département INCIT - Equipe 4 - Mort cellulaire immunogénique appliquée aux traitements du mésothéliome
CRCINA - Centre de recherche de Cancérologie et d'Immunologie / Nantes - Angers
Abstract : Over recent decades, it has become clear that epigenetic abnormalities are involved in the hallmarks of cancer. Histone modifications, such as acetylation, play a crucial role in cancer development and progression, by regulating gene expression, such as for oncogenes or tumor suppressor genes. Therefore, histone deacetylase inhibitors (HDACi) have recently shown efficacy against both hematological and solid cancers. Designed to target histone deacetylases (HDAC), these drugs can modify the expression pattern of numerous genes including those coding for micro-RNAs (miRNA). miRNAs are small non-coding RNAs that regulate gene expression by targeting messenger RNA. Current research has found that miRNAs from a tumor can be investigated in the tumor itself, as well as in patient body fluids. In this review, we summarized current knowledge about HDAC and HDACi in several cancers, and described their impact on miRNA expression. We discuss briefly how circulating miRNAs may be used as biomarkers of HDACi response and used to investigate response to treatment.
Document type :
Journal articles
Complete list of metadatas

Cited literature [157 references]  Display  Hide  Download

Contributor : Elizabeth Bernardo <>
Submitted on : Monday, October 14, 2019 - 2:29:25 PM
Last modification on : Tuesday, February 11, 2020 - 3:12:10 PM


Publisher files allowed on an open archive




Pierre Autin, Christophe Blanquart, Delphine Fradin. Epigenetic Drugs for Cancer and microRNAs: A Focus on Histone Deacetylase Inhibitors. Cancers, MDPI, 2019, 11 (10), pp.1530. ⟨10.3390/cancers11101530⟩. ⟨inserm-02315396⟩



Record views


Files downloads